These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 33474645)

  • 21. Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes.
    Nakamura Y; Tsuji M; Hasegawa H; Kimura K; Fujita K; Inoue M; Shimizu T; Gotoh H; Goto Y; Inagaki M; Oguchi K
    Hemodial Int; 2014 Apr; 18(2):433-42. PubMed ID: 24405885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
    Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
    Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
    Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor.
    Ishii H; Suzaki Y; Miyata Y; Matsui S
    Diabetes Ther; 2019 Aug; 10(4):1369-1380. PubMed ID: 31214997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial.
    Chen Y; Ning G; Wang C; Gong Y; Patel S; Zhang C; Izumoto T; Woerle HJ; Wang W
    J Diabetes Investig; 2015 Nov; 6(6):692-8. PubMed ID: 26543544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.
    Tatosian DA; Cardillo Marricco N; Glasgow XS; DeGroot B; Dunnington K; George L; Gendrano IN; Johnson-Levonas AO; Swearingen D; Kauh E
    Clin Pharmacol Drug Dev; 2016 Sep; 5(5):383-92. PubMed ID: 27627194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials.
    Davidson JA; Lajara R; Aguilar RB; Mattheus M; Woerle HJ; von Eynatten M
    BMJ Open Diabetes Res Care; 2014; 2(1):e000020. PubMed ID: 25452864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telenutrition Education Is Effective for Glycemic Management in People with Type 2 Diabetes Mellitus: A Non-Inferiority Randomized Controlled Trial in Japan.
    Mori H; Taniguchi S; Tamaki Y; Tamaki M; Akehi Y; Kuroda A; Matsuhisa M
    Nutrients; 2024 Jan; 16(2):. PubMed ID: 38257162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effectiveness and safety of linagliptin within elderly type 2 diabetes mellitus: a meta-analysis and systematic review.
    Wang MJ; Liu JL; Wang N; Han X; Zhang HX
    Minerva Endocrinol (Torino); 2022 Feb; ():. PubMed ID: 35103456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-marketing Study of Linagliptin: A Pilot Study.
    Gomes GKA; Pereira ML; Sanches C; Baldoni AO
    Front Pharmacol; 2019; 10():576. PubMed ID: 31178735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Patient Satisfaction of Dipeptidyl Peptidase-4 Inhibitor After Switching From Once-Daily DPP-4 Inhibitor to Once-Weekly Regimen.
    Suzuki K; Hasegawa K; Watanabe M
    J Clin Med Res; 2018 Aug; 10(8):641-647. PubMed ID: 29977422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of treatment satisfaction, efficacy and safety of dipeptidyl peptidase-4 inhibitors in geriatric patients with type 2 diabetes mellitus: A cross-sectionalcomparative study.
    Singh H; Chakrawarti A; Singh H; Guruprasad P; Gupta YK
    J Family Med Prim Care; 2018; 7(1):70-76. PubMed ID: 29915736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control.
    Kadowaki T; Seino Y; Kaku K; Okamoto T; Kameya M; Sato A; Hirano T; Oshima N; Gantz I; O'Neill EA; Engel SS;
    Diabetes Obes Metab; 2021 Jun; 23(6):1242-1251. PubMed ID: 33512755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
    Isaka Y; Hamano T; Fujii H; Tsujimoto Y; Koiwa F; Sakaguchi Y; Tanaka R; Tomiyama N; Tatsugami F; Teramukai S
    J Am Soc Nephrol; 2021 Mar; 32(3):723-735. PubMed ID: 33547218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Admission Hemoglobin Levels Are Associated With Functional Outcome in Spontaneous Intracerebral Hemorrhage.
    Acosta JN; Leasure AC; Kuohn LR; Both CP; Petersen NH; Sansing LH; Matouk CC; Testai F; Langefeld CD; Woo D; Kamel H; Murthy SB; Qureshi A; Mayer SA; Sheth KN; Falcone GJ
    Crit Care Med; 2021 May; 49(5):828-837. PubMed ID: 33591003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol.
    Jojima T; Sakurai S; Wakamatsu S; Iijima T; Saito M; Tomaru T; Kogai T; Usui I; Aso Y
    Int J Cardiol; 2021 May; 331():243-248. PubMed ID: 33556413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefit of Early Add-on of Linagliptin to Insulin in Japanese Patients With Type 2 Diabetes Mellitus: Randomized-Controlled Open-Label Trial (TRUST2).
    Katsuno T; Shiraiwa T; Iwasaki S; Park H; Watanabe N; Kaneko S; Terasaki J; Hanafusa T; Imagawa A; Shimomura I; Ikegami H; Koyama H; Namba M; Miyagawa JI;
    Adv Ther; 2021 Mar; 38(3):1514-1535. PubMed ID: 33507500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.